399 related articles for article (PubMed ID: 30659409)
1. Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases.
Xiang Z; Yu Y
Front Med; 2019 Feb; 13(1):24-31. PubMed ID: 30659409
[TBL] [Abstract][Full Text] [Related]
2. Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy.
Zhang M; Yang J; Hua W; Li Z; Xu Z; Qian Q
Front Med; 2019 Feb; 13(1):32-44. PubMed ID: 30680606
[TBL] [Abstract][Full Text] [Related]
3. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
5. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.
Budczies J; Bockmayr M; Klauschen F; Endris V; Fröhling S; Schirmacher P; Denkert C; Stenzinger A
Genes Chromosomes Cancer; 2017 Aug; 56(8):651-659. PubMed ID: 28466543
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for Checkpoint Inhibition.
Weber JS
Am Soc Clin Oncol Educ Book; 2017; 37():205-209. PubMed ID: 28561695
[TBL] [Abstract][Full Text] [Related]
7. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
8. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
Choucair K; Morand S; Stanbery L; Edelman G; Dworkin L; Nemunaitis J
Cancer Gene Ther; 2020 Dec; 27(12):841-853. PubMed ID: 32341410
[TBL] [Abstract][Full Text] [Related]
9. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
10. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy.
Li X; Song W; Shao C; Shi Y; Han W
Cell Mol Immunol; 2019 Jan; 16(1):28-39. PubMed ID: 30002451
[TBL] [Abstract][Full Text] [Related]
11. Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms.
Lim SY; Rizos H
Mamm Genome; 2018 Dec; 29(11-12):866-878. PubMed ID: 29968076
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for Immunotherapy: Current Developments and Challenges.
Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
[TBL] [Abstract][Full Text] [Related]
14. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
[TBL] [Abstract][Full Text] [Related]
15. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Music M; Prassas I; Diamandis EP
Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
[TBL] [Abstract][Full Text] [Related]
16. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
17. Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers.
Lee B; Hutchinson R; Wong HL; Tie J; Putoczki T; Tran B; Gibbs P; Christie M
Semin Cancer Biol; 2018 Oct; 52(Pt 2):241-252. PubMed ID: 29258858
[TBL] [Abstract][Full Text] [Related]
18. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance.
Park YJ; Kuen DS; Chung Y
Exp Mol Med; 2018 Aug; 50(8):1-13. PubMed ID: 30135516
[TBL] [Abstract][Full Text] [Related]
19. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
Jardim DL; Goodman A; de Melo Gagliato D; Kurzrock R
Cancer Cell; 2021 Feb; 39(2):154-173. PubMed ID: 33125859
[TBL] [Abstract][Full Text] [Related]
20. Microbial biomarkers for immune checkpoint blockade therapy against cancer.
Adachi K; Tamada K
J Gastroenterol; 2018 Sep; 53(9):999-1005. PubMed ID: 30003334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
